Stifel Initiates Coverage On Jasper Therapeutics with Buy Rating, Announces Price Target of $86
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Ben Burnett initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces a price target of $86.
June 27, 2024 | 9:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Ben Burnett has initiated coverage on Jasper Therapeutics with a Buy rating and set a price target of $86. This positive analyst rating and high price target could boost investor confidence and drive the stock price up in the short term.
The initiation of coverage with a Buy rating and a high price target by a reputable analyst can significantly influence investor sentiment. This is likely to result in increased buying activity and a short-term rise in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100